Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 505-511

  He, Ke ^a   Shi, Jun Cheng ^a   Mao, Xiao Ming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acarbose; Efficacy; Safety; glucosidase inhibitor

Indexed keywords

ACARBOSE; ACARBOSE PLUS METFORMIN; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; FIBRINOGEN; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; NATEGLINIDE; PLACEBO; STARCH; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL DISTENSION; ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE; DIABETES CONTROL; DIARRHEA; DIET THERAPY; DRUG ABSORPTION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FLATULENCE; FOOD INTAKE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POSTPRANDIAL HYPERGLYCEMIA; REVIEW; RISK REDUCTION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84903770732     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S50362     Document Type: Review

References (56)

1. No authors listed. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342(6):381-389.
2. No authors listed. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
3. Choi YJ, Kim HC, Kim HM, Park SW, Kim J, Kim DJ. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1 998-2005. Diabetes Care. 2009;32(11): 2016-2020.
4. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med. 2007;24(5): 451-463.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
6. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3): 397-405.
7. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25(10):1845-1850.
8. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164(19):2147-2155.
9. Monnier L, Colette C, Boniface H. Contribution of postprandial glucose to chronic hyperglycaemia: from the "glucose triad" to the trilogy of "sevens". Diabetes Metab. 2006;32(2):2S11-2S16.
10. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280-285.
11. Peter R, Okoseime OE, Rees A, Owens DR. Postprandial glucose: a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol. 2009;7(1):68-74.
12. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27(1):79-84.
13. Standl E, Schnell O. Alpha-glucosidase inhibitors 2 012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res. 2012;9(3): 163-169.
14. Lebovitz HE. Alpha-Glucosidase inhibitors. Endocrinol Metab Clin North Am. 1997;26(3):539-551.
15. Scheen J, Lefèbvre PJ. Oral antidiabetic agents. A guide to selection. Drugs. 1998;55(2):225-236.
16. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs. 2003;63(10):933-951.
17. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systemic meta-analysis. Clin Ther. 2013;35(6):880-899.
18. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol. 2002;13(1):3-9.
19. Food and Agriculture Organization of the United Nations. FAO Food and Nutrition Paper 83. Globalization of Food Systems in Developing Countries: Impact on Food Security and Nutrition. Rome: UN FAO; 2004. Available from: http://www.fao.org/docrep/007/y5736e/y5736e00.htm. Accessed January 15, 2013.
20. Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig. 2007;27(6):397-405.
21. Hung YJ, Kuo SW, Wang CH, Chang HY, Hsieh SH, Landen H. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Investig. 2006;26(10):559-565.
22. Wang H, Ni Y, Yang S, Li H, Li X, Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp. 2013;75: 88-92.
23. Chan JC, Chan K W, Ho LL, et al. An Asian multicenter clinical trial to assess the effcacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care. 1998;21(7):1058-1061.
24. Pan C, Yang W, Barona J P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25(4):435-441.
25. Li CL, Hung YJ, Qamruddin K, Aziz MF, Stein H, Schmidt B. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;92(1):57-64.
26. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014;2(1):46-55.
27. Gao HW, Xie C, Wang HN, Lin YJ, Hong T P. Benefcial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin. 2007;28(4):534-539.
28. Ju-Ming L, Xiao-Hui G, Xiao-Feng L, Yan-Bing L, Li Y, Yao-Ming X. Effects of nateglinide on postprandial plasma glucose excursion and metabolism of lipids in Chinese patients with type 2 diabetes: 4-week, randomized, active-control, open-label, parallel-group, multicenter trial. Curr Med Res Opin. July 19, 2012. [Epub ahead of print.]
29. Zhou J, Li H, Zhang X, et al. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in Chinese antihyperglycemic agent-naive subjects with type 2 diabetes. Diabetes Technol Ther. 2013;15(6):481-488.
30. Li J, Tian H, Li Q, et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab. 2007;9(4):558-565.
31. Hazama Y, Matsuhisa M, Ohtoshi K, et al. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract. 2006;71(3):251-255.
32. Pan CY, Gao Y, Chen J W, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2003;61(3):183-190.
33. Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol. 2013;12:73.
34. Buse J, Hart K, Minasi L. The PROTECT Study: fnal results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther. 1998;20(2):257-269.
35. Mertes G. Effcacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2 -year surveillance study. Diabetes Res Clin Pract. 1998;40(1):63-70.
36. Scorpiglione N, Belfglio M, Carinci F, et al. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. Eur J Clin Pharmacol. 1999;55(4):239-249.
37. Wu QL, Liu Y P, Lu JM, et al. Effcacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial. J Evid Based Med. 2012;5(3):134-138.
38. Lin BJ, Wu H P, Huang HS, et al. Effcacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications. 2003;17(4):179-185.
39. Wang JS, Lin SD, Lee WJ, et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2011;33(12):1932-1942.
40. Lin SD, Wang JS, Hsu SR, et al. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications. 2011;25(5):332-338.
41. Wang JS, Huang CN, Hung YJ, et al; Acarbose/Metformin Fixed-Dose Combination Study Investigators. Acarbose plus metformin fxed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract. 2013;102(1):16-24.
42. Su JB, Wang XQ, Chen J F, Wu G, Jin Y. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose. Chin Med J (Engl). 2011;124(1):144-147.
43. Hwu CM, Ho LT, Fuh MM, et al; Asian Acarbose Study Group. Acar-bose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes Res Clin Pract. 2003;60(2):111-118.
44. Båvenholm PN, Efendic S. Postprandial hyperglycaemia and vascular damage: the benefts of acarbose. Diab Vasc Dis Res. 2006;3(2): 72-79.
45. Rudofsky G Jr, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res. 2004;36(9): 630-638.
46. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia. 1996;39(4):469-473.
47. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose [ADA abstract 766]. Diabetes. 2004; 53(Suppl 2):A189.
48. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-494.
49. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35(5):1073-1078.
50. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25(1):10-16.
51. Hanefeld M. Cardiovascular benefts and safety profle of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol. 2007;6:20.
52. Derosa G, Maffoli P. Effcacy and safety profle evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther. 2012;34(6):1221-1236.
53. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
54. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
55. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358(24):2630-2633.
56. Derosa G, Maffoli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012;8(5):899-906.